Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 19/20 | 0.67 |
| ▸ | JAK2 | O60674 | 15/20 | 0.67 |
| ▸ | JAK3 | P52333 | 11/20 | 0.50 |
| ▸ | TYK2 | P29597 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21400283 | 0.91 | JAK1 (0.68) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL21383328 | 0.87 | JAK1 (0.51) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL21382971 | 0.85 | JAK1 (0.70) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL21382768 | 0.84 | JAK1 (0.70) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL29708153 | 0.84 | JAK1 (0.70) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL21382792 | 0.84 | JAK1 (0.50) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL21400298 | 0.84 | JAK1 (0.68) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL21382952 | 0.84 | JAK1 (0.54) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL21382712 | 0.84 | JAK1 (0.65) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL21383219 | 0.84 | JAK1 (0.69) | JAK1JAK2JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768272-B1 | JAK INHIBITORS | LIAO XIBIN (US) | 2025-07-30 | — | — | EP | claimed |
| US-11365188-B2 | JAK inhibitors | LIAO XIBIN (US) | 2022-06-21 | — | — | US | claimed |
| US-20210053943-A1 | JAK INHIBITORS | LIAO XIBIN (US) | 2021-02-25 | — | — | US | claimed |
| EP-3768272-B1 | JAK INHIBITORS | LIAO XIBIN (US) | 2025-07-30 | — | — | EP | disclosed |
| US-11365188-B2 | JAK inhibitors | LIAO XIBIN (US) | 2022-06-21 | — | — | US | disclosed |
| US-11365188-B2 | JAK inhibitors | LIAO XIBIN (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210053943-A1 | JAK INHIBITORS | LIAO XIBIN (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210053943-A1 | JAK INHIBITORS | LIAO XIBIN (US) | 2021-02-25 | — | — | US | disclosed |
| WO-2019182924-A1 | JAK INHIBITORS | LIAO XIBIN (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365188-B2 | JAK inhibitors | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885JAK3 3/4885 |
| US-20210053943-A1 | JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.